Olanzapine compared to lithium in mania: a double-blind randomized controlled trial

Publisher Website
Google Scholar
Abstract
Neuroleptics are of established efficacy in mania. Controlled data on the use of olanzapine in mania is however, absent. In this study, 30 patients meeting DSM-IV criteria for mania were randomly allocated to receive either olanzapine or lithium in a 4 week double-blind randomized controlled design. There were no significant outcome differences between the two groups on any of the primary outcome measures, the Brief Psychiatric Rating Scale (lithium 28.2; olanzapine 28.0; P=0.44); Clinical Global Impression (CGI) improvement scale (lithium 2.75, olanzapine 2.36; P=0.163) or the Mania Scale (lithium 13.2, olanzapine 10.2; P=0.315). Olanzapine was however, significantly superior to lithium on the CGI-severity scale at week 4 (lithium 2.83, olanzapine 2.29; P=0.025). Olanzapine did not differ from lithium in terms of treatment emergent extrapyramidal side-effects as measured by the Simpson-Angus Scale. Olanzapine appears to be at least as effective as lithium in the treatment Of mania

This publication has 0 references indexed in Scilit: